| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0009 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.18 | 0.001 |
| mRNA | thapsigargin | GDSC1000 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | -0.093 | 0.001 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.092 | 0.002 |
| mRNA | WH-4-023 | GDSC1000 | pan-cancer | AAC | -0.15 | 0.002 |